NCT01867957View on ClinicalTrials.gov

Efficacy and Safety of Anthrax Vaccine, GC1109

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Anthrax
Interventions
BIOLOGICAL

Low-dose GC1109

50ug/dose

BIOLOGICAL

High-dose GC1109

100ug/dose

BIOLOGICAL

Low-dose Placebo

0.9% Saline 0.5 mL

BIOLOGICAL

High-dose Placebo

0.9% Saline 1.0 mL

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
collaborator

Green Cross Corporation

INDUSTRY

collaborator

LSK Global Pharma Services Co. Ltd.

UNKNOWN

lead

Seoul National University Hospital

OTHER